样式: 排序: IF: - GO 导出 标记为已读
-
Development and validation of an LC-MSMS method to quantify creatinine from dried blood spots J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2024-03-06 Carlos Torres, Rogers A. Muldrow, Anissa R. Naranjo, Steven W. Cotten, Christina C. Pierre, Dina N. Greene
Screening for chronic kidney disease relies on accurate and precise creatinine measurements. Traditionally, creatinine is measured in serum or plasma using high-throughput chemistry analyzers. However, dried blood spots (DBS) can also be utilized to improve testing access. Samples were obtained from a 6 mm DBS punch, which was reconstituted in water before undergoing an acetonitrile crash. The resulting
-
Matrix-matched calibrators are necessary for robust and high-quality dried blood spots lead screening assays by inductively coupled plasma-mass spectrometry. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-11-02 Jessica M Colón Franco,Rogers A Muldrow,Wendy Cieslak,Patrick DeArmond,Cody Orahoske,Drew Payto,Dina N Greene,Dustin Bunch
Background and aims Reliable lead screening methods are necessary to support early identification of lead exposure in children. Sample collection using dried blood spots (DBS) offers advantages compared to traditional venipuncture and capillary collection. Here, we describe and compare three lead DBS inductively coupled plasma-mass spectrometry (ICP-MS) methods for lead screening. Materials and methods
-
Improving LC-MS/MS measurements of steroids with differential mobility spectrometry. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-10-09 Yubo Chai,Stefan K G Grebe,Anthony Maus
Introduction Steroid measurements are important for diagnosis and monitoring of many conditions and treatment regiments; however, due to structural and chemical similarities amongst steroids, these analyses are challenging, even for highly specific techniques such as liquid chromatography-tandem mass spectrometry (LC-MS/MS). Differential mobility spectrometry (DMS) has the potential to improve these
-
Assessing variations in manual pipetting: An under-investigated requirement of good laboratory practice. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-10-08 Xue Li Guan,Dorothy Pei Shan Chang,Zhen Xuan Mok,Bernett Lee
Pipettes are essential tools for biomedical and analytical laboratories, analogous to workstations for computer scientists. Variation in pipetting is a known unknown, as it is generally accepted that variations exist, but thus far, there have been limited studies on the extent of these variations in practice. In this mini-review, we highlight how manual pipetting is a key technique in the laboratory
-
Comparison of liquid chromatography-high-resolution tandem mass spectrometry (MS2) and multi-stage mass spectrometry (MS3) for screening toxic natural products. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-09-30 Ruben Yiqi Luo,Kate Comstock,Caroline Ding,Alan H B Wu,Kara L Lynch
Background Liquid chromatography-high-resolution mass spectrometry (LC-HR-MS) has emerged as a powerful analytical technology for compound screening in clinical toxicology. To evaluate the potential of LC-HR-MS3 in detecting toxic natural products, a spectral library of 85 natural products (79 alkaloids) that contains both MS2 and MS3 mass spectra was constructed and used to identify the natural products
-
GC-MS and GC-MS/MS measurement of malondialdehyde (MDA) in clinical studies: Pre-analytical and clinical considerations. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-08-05 Dimitrios Tsikas
Malondialdehyde (MDA; 1,3-propanedial, OHC-CH2-CHO) is one of the most frequently measured biomarkers of oxidative stress in plasma and serum. L-Arginine (Arg) is the substrate of nitric oxide synthases (NOS), which convert L-arginine to nitric oxide (NO) and L-citrulline. The Arg/NO pathway comprises several members, including the endogenous NOS-activity inhibitor asymmetric dimethylarginine (ADMA)
-
Automated LC-MS/MS: Ready for the clinical routine Laboratory? J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-08-02 Sina Junger,Miriam Hoene,Maria Shipkova,Gudrun Danzl,Christof Schöberl,Andreas Peter,Rainer Lehmann,Eberhard Wieland,Helmine Braitmaier
Background Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a sensitive method with high specificity. However, its routine use in the clinical laboratory is hampered by its high complexity and lack of automation. Studies demonstrate excellent analytical performance using the first fully automated LC-MS/MS for 25-hydroxy vitamin D and immunosuppressant drugs (ISD) in hospital routine laboratories
-
The pipetting Olympics: Propagating proper pipetting a priori in clinical LC-MS/MS analysis. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-07-13 Matthew L Crawford,Christopher M Shuford,Russell P Grant
Introduction Engaging pipetting events were developed to assess and challenge technicians' practical sample handling using matrices common to the clinical laboratory. As correct pipetting stands as a prerequisite for accurate clinical laboratory testing, this helped to understand sources of imprecision and bias attributed to the underlying step of aspirating and dispensing patient samples and internal
-
Practical considerations for accurate determination of free thyroxine by equilibrium dialysis. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-06-23 Ashley Ribera,Li Zhang,Carla Ribeiro,Norma Vazquez,Janet Thonkulpitak,Julianne C Botelho,Uliana Danilenko,Katleen van Uytfanghe,Hubert W Vesper
Background Free thyroxine (FT4) measurement is one of the most requested tests in patient care for diagnosing and treating thyroid-related illnesses. Equilibrium dialysis (ED) is considered the "gold standard" for FT4 measurement; however, several factors have a profound effect on the reliability of FT4 assays and require special consideration. Methods In the current study, we focused on evaluating
-
Development and clinical application of a liquid chromatography-tandem mass spectrometry-based assay to quantify eight tyrosine kinase inhibitors in human plasma. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-05-12 Fangjun Chen,Wenda Chen,Zhenxin Wang,Yingfei Peng,Beili Wang,Baishen Pan,Wei Guo
Introduction Tyrosine kinase inhibitors (TKIs) are widely used in tumor treatment. The detection of these medicines by liquid chromatography-tandem mass spectrometry (LC-MS/MS) can avoid the interference of structurally similar compounds. Objectives This study aimed to develop and validate a new LC-MS/MS assay for the quantification of eight tyrosine kinase inhibitors in human plasma and to preliminarily
-
An introduction from the Laboratory Developed Tests special issue guest editors. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-05-09 Melissa M Budelier,Mark A Marzinke,Jacqueline A Hubbard
-
Analysis of monoclonal immunoglobulins from bone marrow plasma cells using immunopurification and LC-MS. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-04-15 David R Barnidge,Angela Dispenzieri,Dragan Jevremovic,David L Murray
Introduction Clonal plasma cells secrete immunoglobulins, each with the exact same amino acid sequence, that are referred to as monoclonal immunoglobulins. The monoclonal heavy chain and light chain secreted from clonal plasma cells have the same molecular mass prior to the addition of post-translational modifications (PTMs) since their amino acid sequences are the same. Objective To examine the molecular
-
Measurement of kynurenine pathway metabolites by tandem mass spectrometry. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-04-15 Sedat Abusoglu,Duygu Eryavuz Onmaz,Gulsum Abusoglu,Fatma Humeyra Yerlikaya,Ali Unlu
Objectives Recent studies have shown that derangements in kynurenine pathway metabolite levels are associated with various pathologies such as neurodegenerative diseases, schizophrenia, depression, bipolar disorder, rheumatoid arthritis, and cancer. Therefore, reliable, accurate, fast, and multiplex measurement methods for kynurenines have become increasingly important. This study aimed to validate
-
A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-04-13 Nittaya Limsuwanachot,Budsaba Rerkamnuaychoke,Pimjai Niparuck,Roongrudee Singdong,Adcharee Kongruang,Piyapha Hirunpatrawong,Thanaporn Siriyakorn,Pa-Thai Yenchitsomanus,Teerapong Siriboonpiputtana
Introduction The therapeutic strategy and management of chronic myeloid leukemia (CML) have rapidly improved with the discovery of effective tyrosine kinase inhibitors (TKIs) to target BCR::ABL1 oncoprotein. However, nearly 30% of patients develop TKI resistance due to acquired mutations on the tyrosine kinase domain (TKD) of BCR::ABL1. Methods We customized a mass array panel initially intended to
-
Evaluating the performance of the Roche FEN2 fentanyl immunoassay and its clinical implementation: The role of LDT-based mass spectrometry testing. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-03-09 Marlen Menlyadiev,Raymond T Suhandynata,Kyle Lund,Michael J Kelner,Robert L Fitzgerald
Introduction While laboratory-developed tests (LDTs) using liquid chromatography tandem mass spectrometry (LC-MS/MS) are widely employed to support the development of FDA-cleared drug immunoassays, their significance in the clinical implementation and evaluation of such assays is often overlooked. This paper reports on the important role of LC-MS/MS LDTs in demonstrating improved performance of the
-
Mass spectrometry quantitation of immunosuppressive drugs in clinical specimens using online solid-phase extraction and accurate-mass full scan-single ion monitoring. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-03-07 Priscilla S-W Yeung,Paige Miller,Tran Bao Lai-Nyugen,Phil Cheng,Amira Ibrahim,Run-Zhang Shi,Raffick A R Bowen,Ruben Yiqi Luo
Introduction Therapeutic drug monitoring (TDM) of immunosuppressants is essential for optimal care of transplant patients. Immunoassays and liquid chromatography-mass spectrometry (LC-MS) are the most commonly used methods for TDM. However, immunoassays can suffer from interference from heterophile antibodies and structurally similar drugs and metabolites. Additionally, nominal-mass LC-MS assays can
-
Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-03-05 Judith A Stone,J Grace van der Gugten
Tandem mass spectrometry is an important analytical tool for clinical laboratories, but tests developed and validated in-house (laboratory developed tests, or LDTs) require special consideration. In late 2022, the forecast for United States (U.S.) federal regulation of LDTs changed unexpectedly when the VALID Act was not passed by the U.S. Congress. This Act would have modified the Food and Drug Administration's
-
Pediatric laboratory developed tests filling the gaps for children in crisis. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-03-03 Dustin R Bunch
-
A case series evaluation of comprehensive drug testing in the pediatric acute care setting. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-03-02 Kara L Lynch
Introduction Drug testing typically follows a one-size-fits-all approach that is inadequate in some clinical scenarios, such as child maltreatment, neglect, and unintentional drug exposure. Results from immunoassay-based testing, which are non-specific, insensitive, and far from comprehensive, can lead to unintended consequences for children and their families. Objectives The objective of this retrospective
-
Comparison of two highly sensitive benzodiazepine immunoassay lab developed tests for urine drug testing in clinical specimens. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-03-01 Kyle Lund,Marlen Menlyadiev,Kyunghoon Lee,Michael J Kelner,Robert L Fitzgerald,Raymond T Suhandynata
Background The VALID Act is a legislative effort that, if enacted, would alter the regulatory requirements of laboratory developed tests (LDTs) used for clinical testing in the United States. Benzodiazepines, which are primarily excreted into urine as glucuronidated metabolites such as lorazepam, cross-react poorly with FDA-cleared immunoassays, leading to false-negatives. This shortfall can be addressed
-
The regulatory landscape of laboratory developed tests: Past, present, and a perspective on the future. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-02-23 Melissa M Budelier,Jacqueline A Hubbard
-
Bridging the gap: The critical role of laboratory developed tests in clinical toxicology. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-02-22 Jaime H Noguez,Christopher D Koch
•Toxicology testing provides valuable information for patient management.•Current in vitro diagnostics (IVDs) are unable to meet all clinical needs.•Lab-developed tests (LDTs) in toxicology can be used to close clinical care gaps.•LDTs in clinical toxicology are almost exclusively mass spectrometry-based methods.
-
UTI detection by PCR: Improving patient outcomes. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-02-20 Brian N Kelly
-
How the VALID Act could affect patient access to laboratory developed testing for therapeutic drug monitoring. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-02-18 Alec Saitman
•LDTs are important to lab medicine as they allow flexibility for laboratories to provide testing that patients need.•Many TDMs are LCMS-based and are considered LDTs.•Some TDMs currently have little to no options for obtaining FDA cleared testing.•The VALID Act may threaten the offering of LDTs in the United States.•The current VALID Act has flaws in its legislations which need to be addressed.
-
Impact of the loss of Laboratory Developed Mass Spectrometry testing at a major academic medical center. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-02-18 K Aaron Geno,Mark A Cervinski
Background Our laboratory historically performed immunosuppressant and definitive opioid testing in-house as laboratory developed (LDT) mass spectrometry-based tests. However, staffing constraints and supply chain challenges associated with the COVID-19 pandemic forced us to refer this testing to a national reference laboratory. The VALID Act could impose onerous requirements for laboratories to develop
-
Pre-analytical sample handling standardization for reliable measurement of metabolites and lipids in LC-MS-based clinical research. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-02-17 A Sens,S Rischke,L Hahnefeld,E Dorochow,S M G Schäfer,D Thomas,M Köhm,G Geisslinger,F Behrens,R Gurke
The emerging disciplines of lipidomics and metabolomics show great potential for the discovery of diagnostic biomarkers, but appropriate pre-analytical sample-handling procedures are critical because several analytes are prone to ex vivo distortions during sample collection. To test how the intermediate storage temperature and storage period of plasma samples from K3EDTA whole-blood collection tubes
-
Small molecule biomarker discovery: Proposed workflow for LC-MS-based clinical research projects. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-02-17 S Rischke,L Hahnefeld,B Burla,F Behrens,R Gurke,T J Garrett
Mass spectrometry focusing on small endogenous molecules has become an integral part of biomarker discovery in the pursuit of an in-depth understanding of the pathophysiology of various diseases, ultimately enabling the application of personalized medicine. While LC-MS methods allow researchers to gather vast amounts of data from hundreds or thousands of samples, the successful execution of a study
-
Impact of VALID Act implementation on mass spectrometry-based clinical proteomic laboratory developed tests. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-02-13 Yanchun Lin,Stefani N Thomas
Mass spectrometry (MS)-based clinical proteomic Laboratory Developed Tests (LDTs) for the measurement of protein biomarkers related to endocrinology, cardiovascular disease, cancer, and Alzheimer's disease are gaining traction in clinical laboratories due to their value in supporting diagnostic and treatment decisions for patients. Under the current regulatory landscape, MS-based clinical proteomic
-
Discovery of a biomarker for β-Thalassemia by HPLC-MS and improvement from Proton Transfer Reaction - Parallel Ion Parking. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-02-02 Yuan Lin,Archana M Agarwal,Lissa C Anderson,Alan G Marshall
β-thalassemia is a quantitative hemoglobin (Hb) disorder resulting in reduced production of Hb A and increased levels of Hb A2. Diagnosis of β-thalassemia can be problematic when combined with other structural Hb variants, so that the separation approaches in routine clinical centers are not sufficiently decisive to obtain accurate results. Here, we separate the intact Hb subunits by high-performance
-
Molecular diagnostics and the laboratory developed test: A tale of success and the potential impacts of increased regulation. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-02-01 Gregory J Tsongalis
-
A persistently febrile patient post-bone marrow transplant. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-01-28 Ashley R Rackow,Claire E Knezevic
-
Clinical utility of laboratory developed mass spectrometry assays for steroid hormone testing. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-01-28 Deborah French
-
Pre-analytical conditions influencing analysis of folate in dried plasma microsamples. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-01-24 Christopher M Shuford,Evan W McConnell,Stacy Dee,Russell P Grant
Introduction Determination of folate insufficiency is of considerable interest given its importance in fetal development and red blood cell formation; however, access to blood tests may be limited due to the requirement for phlebotomy as well as controlled temperature shipping of blood specimens to laboratories for testing due to the inherent instability of folate and its vitamers. Methods An LC-MS/MS
-
Effects of sample matrix in the measurement of antithrombin by LC-MS: A role for immunocapture. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2023-01-07 M Kruijt,N P M Smit,J J van Ham,C M Cobbaert,L R Ruhaak
Introduction The sample matrix composition, which is greatly affected by the type of blood collection tube used during phlebotomy, is of major importance in laboratory testing as it can influence test results. We developed an LC-MRM-MS test to molecularly characterize antithrombin in citrate plasma. The test principle differs greatly from traditional laboratory tests and the influence of varying plasma
-
Development of Tier 2 LC-MRM-MS protein quantification methods for liquid biopsies. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-12-23 Nina Diederiks,Cor J Ravensbergen,Maxim Treep,Madelein van Wezel,Matt Kuruc,L Renee Ruhaak,Rob A E M Tollenaar,Christa M Cobbaert,Yuri E M van der Burgt,Wilma E Mesker
In the pursuit of personalized diagnostics and tailored treatments, quantitative protein tests contribute to a more precise definition of health and disease. The development of new quantitative protein tests should be driven by an unmet clinical need and performed in a collaborative effort that involves all stakeholders. With regard to the analytical part, mass spectrometry (MS)-based platforms are
-
Method validation of multi-element panel in whole blood by inductively coupled plasma mass spectrometry (ICP-MS). J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-12-17 Amol O Bajaj,Rebecca Parker,Candice Farnsworth,Christian Law,Kamisha L Johnson-Davis
Background Analytical methods to measure trace and toxic elements are essential to evaluate exposure and nutritional status. A ten-element panel was developed and validated for clinical testing in whole blood. Retrospective data analysis was conducted on patient samples performed at ARUP Laboratories. Methods A method was developed and validated to quantify ten elements in whole blood by ICP-MS. Fifty
-
Semi-automated serum steroid profiling with tandem mass spectrometry. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-12-15 Sophie Rakete,Tom Schubert,Michael Vogeser
Objectives Highly selective and sensitive multi-analyte methods for the analysis of steroids are attractive for the diagnosis of endocrine diseases. Commercially available kits are increasingly used for this purpose. These methods involve laborious solid phase extraction, and the respective panels of target analytes are incomplete. We wanted to investigate whether an improvement of kit solutions is
-
A novel fully-automated method to measure steroids in serum by liquid chromatography-tandem mass spectrometry. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-12-15 François Fraissinet,Tony Pereira,Alizée Violin,Guillaume Feugray,Kalyane Bach-Ngohou,Valéry Brunel
Background Steroids play a key role in numerous physiological processes. Steroid determination is a useful tool to explore various endocrine diseases. Because of its specificity, mass spectrometry is considered to be a reference method for the determination of steroids in serum compared to radioimmunoassay. This technology could progress towards more automation for the optimal organization of clinical
-
Validation of a quantitative multiplex LC-MS/MS assay of carvedilol, enalaprilat, and perindoprilat in dried blood spots from heart failure patients and its cross validation with a plasma assay. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-12-12 Andre Joubert,Anton Joubert,Marthinus van der Merwe,Jennifer Norman,Sandra Castel,Paolo Denti,Karen Sliwa,Gary Maartens,Phumla Sinxadi,Lubbe Wiesner
Introduction Adherence to medication is an important determinant of outcomes in chronic diseases like heart failure. Drug assays provide objective adherence biomarkers. Dried blood spots (DBS) are appealing samples for drug assays due to less demanding transportation and storage requirements. Objectives To analytically validate a LC-MS/MS method for the simultaneous quantification of carvedilol, enalaprilat
-
Oxidized LDL is stable in human serum under extended thawed-state conditions ranging from -20 °C to room temperature. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-12-09 Nilojan Jehanathan,Erandi P Kapuruge,Stephen P Rogers,Stacy Williams,Yunro Chung,Chad R Borges
Introduction Oxidized LDL (oxLDL) is formed by the spontaneous reaction between aldehyde byproducts of lipid peroxidation and lysine residues of apolipoprotein B within LDL. Clinically, oxLDL is used as a marker of coronary artery disease and predictor of metabolic syndrome risk. Despite its popularity as a clinical marker, no systematic studies of oxLDL stability, in which serum or plasma has been
-
The VALIDity of Laboratory Developed Tests: Leave it to the experts? J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-12-09 Mark A Marzinke,William Clarke,Dennis J Dietzen,Andrew N Hoofnagle,Gwendolyn A McMillin,Maria Alice V Willrich
-
LC-MS/MS method for simultaneous quantification of ten antibiotics in human plasma for routine therapeutic drug monitoring. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-11-18 Mirjana Radovanovic,Richard O Day,Graham D R Jones,Peter Galettis,Ross L G Norris
Background Optimizing antimicrobial therapy to attain drug exposure that limits the emergence of resistance, effectively treats the infection, and reduces the risk of side effects is of a particular importance in critically ill patients, in whom normal functions are augmented or/and are infected with pathogens less sensitive to treatment. Achievement of these goals can be enhanced by therapeutic drug
-
Corrigendum to "Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease" [Clin. Mass Spectrom. 14 (Part B) (2019) 74-82]. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-09-28 Karl Hansson,Rahil Dahlén,Oskar Hansson,Elin Pernevik,Ross Paterson,Jonathan M Schott,Nadia Magdalinou,Henrik Zetterberg,Kaj Blennow,Johan Gobom
[This corrects the article DOI: 10.1016/j.clinms.2019.07.002.].
-
Corrigendum to "Instability of 7-aminoclonazepam in frozen storage conditions" [Clin. Mass Spectrom. 9 (2018) 23-24]. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-09-24 Jayme L Dahlin,Athena K Petrides
[This corrects the article DOI: 10.1016/j.clinms.2018.07.002.].
-
A distributable LC-MS/MS method for the measurement of serum thyroglobulin. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-09-19 Junyan Shi,William S Phipps,Benjamin Y Owusu,Clark M Henderson,Thomas J Laha,Jessica O Becker,Morteza Razavi,Michelle A Emrick,Andrew N Hoofnagle
Background Despite its clear advantages over immunoassay-based testing, the measurement of serum thyroglobulin by mass spectrometry remains limited to a handful of institutions. Slow adoption by clinical laboratories could reflect limited accessibility to existing methods that have sensitivity comparable to modern immunoassays, as well as a lack of tools for calibration and assay harmonization. Methods
-
Validation of atovaquone plasma levels by liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring in pediatric patients. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-09-14 Thomas D Horvath,Izmarie Poventud-Fuentes,Lily Olayinka,Asha James,Sigmund J Haidacher,Kathleen M Hoch,Alexandra M Stevens,Anthony M Haag,Sridevi Devaraj
Background Atovaquone has traditionally been used as an antiparasitic and antifungal agent, but recent studies have shown its potential as an anticancer agent. The high variability in atovaquone bioavailability highlights the need for therapeutic drug monitoring, especially in pediatric patients. The goal of our study was to develop and validate the performance of an assay to quantify atovaquone plasma
-
Imaging mass spectrometry reveals complex lipid distributions across Staphylococcus aureus biofilm layers. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-09-13 Emilio S Rivera,Andy Weiss,Lukasz G Migas,Jeffrey A Freiberg,Katerina V Djambazova,Elizabeth K Neumann,Raf Van de Plas,Jeffrey M Spraggins,Eric P Skaar,Richard M Caprioli
Introduction Although Staphylococcus aureus is the leading cause of biofilm-related infections, the lipidomic distributions within these biofilms is poorly understood. Here, lipidomic mapping of S. aureus biofilm cross-sections was performed to investigate heterogeneity between horizontal biofilm layers. Methods S. aureus biofilms were grown statically, embedded in a mixture of carboxymethylcellulose/gelatin
-
Corrigendum to "Observation of a positive interference in LC-MS/MS measurement of d6-25-OH-vitamin D3" [Clin. Mass Spectrom. 3 (2017) 22-24]. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-09-09 Danielle Fortuna,Warren R Korn,Matthew J Brune,Xiang He,Alexandre Y Wang,John M Hevko,Douglas F Stickle
[This corrects the article DOI: 10.1016/j.clinms.2017.06.001.].
-
Molecular phenotyping approaches for the detection and monitoring of carbapenem-resistant Enterobacteriaceae by mass spectrometry. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-09-06 Breanna Dixon,Waqar M Ahmed,Tim Felton,Stephen J Fowler
Antimicrobial resistance is increasing in prevalence and there is a clear need for the development of rapid detection methods in clinical diagnostics. This review explores -omics studies utilising mass spectrometry to investigate the molecular phenotype associated with carbapenem resistance. Whilst the specific mechanisms of carbapenem resistance are well characterised, the resistant phenotype is poorly
-
Advances in MS instrumentation: The present and future of the clinical lab. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-09-05 Christopher D Chouinard
-
Corrigendum to "Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs" [Clin. Mass Spectrom. 14(Part A) (2019) 34-45]. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-08-13 Johanna Kuhlin,Marieke G G Sturkenboom,Samiksha Ghimire,Ioana Margineanu,Simone H J van den Elsen,Noviana Simbar,Onno W Akkerman,Erwin M Jongedijk,Remco A Koster,Judith Bruchfeld,Daan J Touw,Jan-Willem C Alffenaar
[This corrects the article DOI: 10.1016/j.clinms.2018.10.002.].
-
Corrigendum to "Analytical validation of protein biomarkers for risk of spontaneous preterm birth" [Clin. Mass Spectrom. 3 (2017) 25-38]. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-08-09 Chad Bradford,Rob Severinsen,Trina Pugmire,Matison Rasmussen,Kathryn Stoddard,Yuta Uemura,Spencer Wheelwright,Marija Mentinova,Daniel Chelsky,Stephen W Hunsucker,Paul Kearney,Durlin Hickok,Tracey C Fleischer,Ilia Ichetovkin,J Jay Boniface,Gregory C Critchfield,John M Peltier
[This corrects the article DOI: 10.1016/j.clinms.2017.06.002.].
-
Haptoglobin polymorphism affects its N-glycosylation pattern in serum. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-07-25 M Kohansal-Nodehi,M Swiatek-de Lange,G Tabarés,H Busskamp
Introduction Haptoglobin (Hp) is an abundant acute-phase protein secreted mainly by the liver into the bloodstream. There are three Hp protein phenotypes (Hp type 1-1, 2-1, and 2-2), which differ in the number of α- and β-chains, type of α-chain (the β-chain type remains the same in all the Hp phenotypes), and the polymers that they form via disulfide bonds. Hp has four N-glycosylation sites on the
-
Targeted metabolic profiling of urinary steroids with a focus on analytical accuracy and sample stability. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-07-25 Nora Vogg,Tobias Müller,Andreas Floren,Thomas Dandekar,Oliver Scherf-Clavel,Martin Fassnacht,Matthias Kroiss,Max Kurlbaum
Introduction Preoperative diagnostic workup of adrenal tumors is based on imaging and hormone analyses, but charged with uncertainties. Steroid profiling by liquid chromatography tandem mass spectrometry (LC-MS/MS) in 24-h urine has shown potential to discriminate benign and malignant adrenal tumors. Our aim was to develop and validate a specific and accurate LC-MS/MS method for the quantification
-
Development and application of a High-Resolution mass spectrometry method for the detection of fentanyl analogs in urine and serum. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-07-22 Yu Zhang,John C Halifax,Christina Tangsombatvisit,Cassandra Yun,Shaokun Pang,Shirin Hooshfar,Alan H B Wu,Kara L Lynch
Introduction The use of illicitly manufactured synthetic opioids, specifically fentanyl and its analogs, has escalated exponentially in the United States over the last decade. Due to the targeted nature of drug detection methods in clinical laboratories and the ever-evolving list of synthetic opioids of concern, alternative analytical approaches are needed. Methods Using the fentanyl analog screening
-
Critical need to assess modified and un-modified peptides in C-peptide standard materials. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-07-22 Zengru Wu,Kuanysh Kabytaev,Jianying Mu,Shawn Connolly,Nigel J Clarke,Randie Little,Michael J McPhaul
-
Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-07-22 Erik I Hallin,Trond Trætteberg Serkland,Kjell-Morten Myhr,Øivind Grytten Torkildsen,Silje Skrede
Introduction Ocrelizumab is a monoclonal anti-CD20 antibody approved for the treatment of multiple sclerosis (MS). The clinical value of therapeutic drug monitoring (TDM) for this antibody in treatment of MS is unknown, and an adequately specific and precise quantitation method for ocrelizumab in patient serum could facilitate investigation. Liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based
-
Simple, high-throughput measurement of gut-derived short-chain fatty acids in clinically relevant biofluids using gas chromatography-mass spectrometry. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-07-16 Joshua T Bain,Maarten W Taal,Nicholas M Selby,James C Reynolds,Liam M Heaney
Introduction The quantitative measurement of circulating gut bacteria-derived metabolites has increased in recent years due to their associations with health and disease. While much of the previous attention has been placed on metabolites considered as deleterious to health, a shift to the investigation of short-chain fatty acids (SCFAs) as potential health promotors has been observed. Objectives To
-
Development and validation of a paper spray mass spectrometry method for the rapid quantitation of remdesivir and its active metabolite, GS-441524, in human plasma. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-06-11 Christine Skaggs,Hannah Zimmerman,Nicholas Manicke,Lindsey Kirkpatrick
Introduction Remdesivir (GS-5734) is a nucleoside analog prodrug with antiviral activity against several single-stranded RNA viruses, including the novel severe respiratory distress syndrome virus 2 (SARS-CoV-2). It is currently the only FDA-approved antiviral agent for the treatment of individuals with COVID-19 caused by SARS-CoV-2. However, remdesivir pharmacokinetics/pharmacodynamics (PK/PD) and
-
Multiplexed quantification of insulin and C-peptide by LC-MS/MS without the use of antibodies. J. Mass Spectrom. Adv. Clin. lab (IF 2.1) Pub Date : 2022-06-10 North Foulon,Elisha Goonatilleke,Michael J MacCoss,Michelle A Emrick,Andrew N Hoofnagle
Introduction The measurement of insulin and C-peptide provides a valuable tool for the clinical evaluation of hypoglycemia. In research, these biomarkers are used together to better understand hyperinsulinemia, hepatic insulin clearance, and beta cell function. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is an attractive approach for the analysis of insulin and C-peptide because the platform